PT  - JOURNAL ARTICLE
AU  - Rabab El Wahsh
AU  - Ramadan Bakr
AU  - Mohamad Zamzam
AU  - Amany Farag
TI  - Tuberculosis status in Minoufiya Governorate, Egypt
DP  - 2011 Sep 01
TA  - European Respiratory Journal
PG  - p4144
VI  - 38
IP  - Suppl 55
4099  - http://erj.ersjournals.com/content/38/Suppl_55/p4144.short
4100  - http://erj.ersjournals.com/content/38/Suppl_55/p4144.full
SO  - Eur Respir J2011 Sep 01; 38
AB  - Introduction: TB is still the most common infectious disease worldwide. In terms of incidence, Egypt is ranked among the mid-level incidence countries.Aim: To provide baseline information for assessment of the epidemiological trends and the impact of TB control interventions.Patients & methods: This was a retrospective epidemiological study including pulmonary TB patients who were diagnosed in Minoufiya Governorate, Egypt from January 2003 to December 2008. Epidemiological data, clinical presentation and examination, radiological examination, laboratory investigations, contact investigations were acquired for all patients.Results: Incidence of pulmonary TB in Minoufiya Governorate in the studied years was 5.1 per 100,000 populations. A higher percentage of pulmonary TB cases was found in males (68.3%), in rural areas (83.7%), and in middle aged persons (25–54 years) 53.8%. The majority of patients were new cases (91.9%) and most patients received CAT I drugs. There was a good response to anti-tuberculous therapy with rapid DSM conversion in most cases. The cure rate at the end of treatment reached about 80%. Treatment outcome was significantly higher with ages (15–54 year), (p<0.001). Outcome was also better in males than females (p<0.05), in rural than urban areas (p<0.001), and in patients treated with CAT-I drugs (p<0.05). Direct smear microscopy (DSM) was positive only in two of 546 contacts.Conclusion: Minoufiya Governorate is one of the moderately affected governorates with pulmonary TB in Egypt, with good control measures done by the health authorities. Middle aged males and rural residents are the most affected groups. Most cases are new with a minority of drug resistant or chronic cases.